Form 4: Regulus Therapeutics Executive Acquires Shares Following Vesting of Performance-Based Restricted Stock Units

Christopher Aker, a Senior VP and General Counsel at Regulus Therapeutics, acquired shares of common stock following the vesting of performance-based restricted stock units.

Summary

• Christopher Aker, a Senior VP and General Counsel at Regulus Therapeutics, acquired shares of common stock.
• The acquisitions resulted from the vesting of restricted stock units (RSUs) that were granted on August 10, 2023, and January 12, 2024.
• The RSUs vested upon achievement of specified performance-based milestones.
• 50% of the shares from each grant vested immediately upon meeting the performance criteria.
• The remaining 50% of the shares from each grant will vest on the one-year anniversary of the vesting commencement date, contingent on Aker's continued service to Regulus.
• Aker acquired 66,625 shares at $1.36 per share and 17,500 shares at $1.30 per share on January 9, 2025.
• Following these transactions, Aker directly owns 93,181 shares of Regulus Therapeutics common stock.

Sentiment

Score: 7

Explanation: The document indicates positive progress with the achievement of performance milestones, leading to the vesting of RSUs. This is a positive sign for the company, but it is a routine filing and not a major event.

Positives

• The vesting of performance-based RSUs indicates that the company has achieved certain milestones.
• The acquisition of shares by a company executive can be seen as a positive sign of confidence in the company's future.

Future Outlook

The remaining 50% of the RSUs from both grants will vest on the one-year anniversary of the vesting commencement date, subject to Aker's continued service to Regulus.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when executives acquire or dispose of company stock. It reflects the compensation structure of the company and the alignment of executive interests with shareholder value.

Comparison to Industry Standards

• The use of performance-based restricted stock units is a common practice in the biotechnology industry to incentivize executives and align their interests with the company's success.
• Many biotech companies use similar vesting schedules, with a portion vesting upon achievement of milestones and the remainder vesting over time.
• The specific vesting terms and performance criteria are unique to Regulus Therapeutics and are not directly comparable to other companies without further information.

Stakeholder Impact

• Shareholders may view the vesting of RSUs and subsequent share acquisition by an executive as a positive sign of the company's progress and management's confidence.
• Employees may see this as a positive sign of the company's performance and the potential for their own equity-based compensation to vest in the future.

Next Steps

• The remaining 50% of the RSUs will vest on the one-year anniversary of the vesting commencement date, subject to Aker's continued service to Regulus.

Key Dates

Keywords

Regulus Therapeutics, Christopher Aker, Restricted Stock Units, RSUs, Share Acquisition, Vesting, Performance-Based Milestones, Insider Trading, SEC Form 4